Physician profile
Paul Massoud
NPI 1831181882
$13,268.11
in general payments reported to CMS, 2019-2025
67 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,055 · 2020: $1,041 · 2021: $2,567 · 2022: $2,504 · 2023: $2,108 · 2024: $1,305 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,101.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,964.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,373.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,313.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,090.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $655.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $480.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $396.05 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $387.84 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $377.79 | 2021-2025 | |
| Amarin Pharma, INC. | $376.24 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.08 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $322.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $294.18 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Allergan, INC. | $279.15 | 2019-2021 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Massoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.